British Journal of Haematology | 2019
Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study
Abstract
Bang, S.M., Kyle, R.A., Rajkumar, S.V. & Kumar, S. (2013) Treatment patterns and outcomes in elderly patients with multiple myeloma. Leukemia, 27, 971–974. Bringhen, S., Mateos, M., Zweegman, S., Larocca, A., Falcone, A., Oriol, A., Rossi, D., Cavalli, M., Wijermans, P., Ria, R., Offidani, M., Lahuerta, J., Liberati, A., Mina, R., Callea, V., Schaafsma, M., Cerrato, C., Marasca, R., Franceschini, L., Evangelista, A., Teruel, A., Van der Holt, B., Montefusco, V., Ciccone, G., Boccadoro, M., San Miguel, J., Sonneveld, P. & Palumbo, A. (2013) Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica, 98, 980–987. Cerrato, C., Di Raimondo, F., De Paoli, L., Spada, S., Patriarca, F., Crippa, C., Mina, R., Guglielmelli, T., Ben-Yehuda, D., Oddolo, D., Nozzoli, C., Angelucci, E., Cascavilla, N., Rizzi, R., Rocco, S., Baldini, L., Ponticelli, E., Marcatti, M., Cangialosi, C., Caravita, T., Benevolo, G., Ria, R., Nagler, T., Musto, P., Tacchetti, P., Corradini, P., Offidani, M., Palumbo, A., Petrucci, M., Boccadoro, M. & Gay, F. (2018) Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. Journal of Cancer Research and Clinical Oncology, 144, 1357–1366. Dimopoulos, M., Kastritis, E., Delimpasi, S, Katodritou, E., Hatzimichael, E., Kyrtsonis, M., Repousis, P., Tsirogianni, M., Kartasis, Z., Parcharidou, A., Michael, M., Michalis, E., Tsatalas, C., Stefanoudaki, E., Hatjiharissi, E., Gika, D., Symeonidis, A., Terpos, E., Zervas, K. & Greek Myeloma Study Group (2012) Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. European Journal of Haematology, 89, 10–15. Greipp, P., San Miguel, J., Durie, B., Crowley, J., Barlogie, B., Blad e, J., Boccadoro, M., Child, J., Avet-Loiseau, H., Kyle, R., Lahuerta, J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412–3420. Panitsas, F., Kothari, J., Vallance, G., Djebbari, F., Ferguson, L., Sultanova, M. & Ramasamy, K. (2018) Treat or palliate: outcomes of very elderly myeloma patients. Haematologica, 103, e32–e34. San Miguel, J., Schlag, R., Khuageva, N., Dimopoulos, M., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M., Palumbo, A., Samoilova, O., Dmoszynska, A., Abdulkadyrov, K., Schots, R., Jiang, B., Mateos, M., Anderson, K., Esseltine, D., Liu, K., Cakana, A., van de Velde, H., Richardson, P. & VISTA Trial Investigators (2008) Bortezomib plus melphalan and prednisone for multiple myeloma. New England Journal of Medicine, 359, 906–197. Turesson, I., Bjorkholm, M., Blimark, C., Kristinsson, S., Velez, R. & Landgren, O. (2018) Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. European Journal of Haematology, 101, 237–244. Wisløff, F., Gulbrandsen, N., Hjorth, M., Lenhoff, S. & Fayers, P. (2005) Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. European Journal of Haematology, 75, 293–298.